# Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly

> **NCT02451969** · PHASE3 · COMPLETED · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 1760 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** investigational 23-valent PPV
- **BIOLOGICAL:** control 23-valent PPV

## Key facts

- **NCT ID:** NCT02451969
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2015-06
- **Final completion:** 2017-02
- **Target enrollment:** 1760 (ACTUAL)
- **Last updated:** 2017-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02451969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02451969, "Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02451969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*